Loading...
Market
Percentage Change in GLP-1 Prescriptions for Obesity by Mid-2025?
3
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
Decrease or no change • 25%
Truveta Research's GLP-1 monitoring report or similar industry reports
Story
Surge in Wegovy, Zepbound Use to Reduce U.S. Calorie Intake by 10 Quadrillion by 2030
Oct 15, 2024, 01:00 AM
A surge in the use of GLP-1 drugs, including Wegovy and Zepbound, is projected to significantly reduce calorie intake in U.S. adults by 10 quadrillion by 2030, according to a new report. This increase in GLP-1 prescriptions for obesity has been observed alongside a relatively flat prescribing rate for GLP-1s labeled for type 2 diabetes between June and September 2024, as noted in Truveta Research's latest GLP-1 monitoring report.
View original story
Similar markets
Below 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
Above 40% • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Wegovy • 25%
Ozempic • 25%
Zepbound • 25%
Other • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Eli Lilly gains significant market share • 25%
Eli Lilly maintains current market share • 25%
Eli Lilly loses market share • 25%
No significant change • 25%
Less than 20% • 33%
20% to 40% • 33%
More than 40% • 34%
Eli Lilly > 60% • 25%
Eli Lilly 40-60% • 25%
Novo Nordisk > 60% • 25%
Novo Nordisk 40-60% • 25%
Eli Lilly gains market share • 25%
Novo Nordisk gains market share • 25%
Both gain equally • 25%
Neither gains market share • 25%
Less than 25% • 25%
25-35% • 25%
35-45% • 25%
More than 45% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%